OGT923
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 15 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
Showing 1 to 10 of 15 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2018-002210-12-FR (EUCTR) | 28/04/202120210428 | 26/10/201820181026 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;France;Czech Republic;Canada;Belgium;Poland;Austria;Netherlands;Germany;United Kingdom United States;France;Czech Republic;Canada;Belgium;Poland;Austria;Netherlands;Germany;United Kingdom ... | ||
2 | EUCTR2018-002210-12-NO (EUCTR) | 26/03/202120210326 | 22/09/202020200922 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Norway;Germany;Netherlands United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Norw ... | ||
3 | EUCTR2018-002210-12-IT (EUCTR) | 22/10/202020201022 | 17/06/202120210617 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease - Not applicable A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: [ACT-434964] INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: [ACT-434964] INN or Proposed INN: Lucerastat Other descriptive n ... | IDORSIA PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Germ ... | ||
4 | EUCTR2017-003369-85-NO (EUCTR) | 24/08/202020200824 | 26/06/202020200626 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease A research study to study the effects of a new oral drug called lucerastat in adults with Fabry dise ... | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the e ... | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia;Norway;Germany;Netherlands United States;Spain;Ireland;Austria;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia ... | ||
5 | EUCTR2017-003369-85-IT (EUCTR) | 16/07/202020200716 | 07/10/202020201007 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease A research study to study the effects of a new oral drug called lucerastat in adults with Fabry dise ... | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease - MODIFY A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the e ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: [ACT-434964] INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: [ACT-434964] INN or Proposed INN: Lucerastat Other descriptive n ... | IDORSIA PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 108 | Phase 3 | United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway United States;Finland;Spain;Ireland;Austria;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;A ... | ||
6 | EUCTR2017-003369-85-ES (EUCTR) | 18/05/202020200518 | 25/05/202020200525 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease A research study to study the effects of a new oral drug called lucerastat in adults with Fabry dise ... | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the e ... | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Russian Federation;United Kingdom;Italy;Switzerland;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway United States;Spain;Ireland;Austria;Russian Federation;United Kingdom;Italy;Switzerland;Canada;Belgi ... | ||
7 | EUCTR2017-003369-85-IE (EUCTR) | 18/05/202020200518 | 01/07/201920190701 | A research study to study the effects of a new oral drug called lucerastat in adults with Fabry disease A research study to study the effects of a new oral drug called lucerastat in adults with Fabry dise ... | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the e ... | Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 99 | Phase 3 | United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway United States;Spain;Ireland;Austria;Italy;Switzerland;United Kingdom;Canada;Belgium;Poland;Australia ... | ||
8 | EUCTR2018-002210-12-BE (EUCTR) | 20/03/202020200320 | 27/03/202020200327 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Norway United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Germ ... | ||
9 | EUCTR2018-002210-12-NL (EUCTR) | 12/04/201920190412 | 19/11/201820181119 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 24.1;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Netherlands;Germany;Norway United States;Spain;Ireland;Austria;Italy;United Kingdom;France;Canada;Belgium;Poland;Australia;Neth ... | ||
10 | EUCTR2018-002210-12-GB (EUCTR) | 18/03/201920190318 | 23/10/201820181023 | A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with ... | A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term saf ... | Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] Fabry disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familia ... | Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive name: OGT923 Product Name: Lucerastat Product Code: ACT-434964 INN or Proposed INN: Lucerastat Other descriptive nam ... | Idorsia Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 108 | Phase 3 | United States;Canada;Poland;Belgium;Ireland;Austria;Australia;Netherlands;Germany;United Kingdom |